knowledge -WSS

knowledge

author：entertainment 2025-09-03 14:35:20 - browse：114

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Would Medicare drug price negotiations stall in a shutdown?

WSS

As billionaires fund anti

Mindstrong's demise and the future of mental health care

Crowdfunding for medical bills sidesteps core problem, author says

BIO to announce reorganization, senior leaders expected to depart

Novel spinal cord stimulator treats paralysis without surgery

Data show record exodus of life scientists from academia

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Most antidepressants don't work on kids, teens, study finds

Continuity nursing helped my family in our darkest PICU moments

Brain technologies pose threats that are all too real, experts warn

Virginia high school admissions case could be legal follow

Menendez indictment could see pharma lose a key ally

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Warren pushes Witty on UnitedHealth's control over physicians

ChatGPT in medicine: STAT answers readers' burning questions

Listen: Who gets the credit for GLP

knowledge

Warren pushes Witty on UnitedHealth's control over physicians

FDA advisers vote against ALS treatment from BrainStorm

Intercept Pharmaceuticals sells itself for less than $1 billion

Chemotherapy before breast cancer surgery might fuel metastasis

Covid vaccines: Private market messier than government rollout

Mindstrong's demise and the future of mental health care

entertainment

hotspot

focus

focus